EXELIXIS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.13 USD | +1.14% |
|
+0.91% | -7.75% |
Presenter SpeechAndrew Peters (Analysts)Good morning, and welcome to the 2017 Deutsche Bank He...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
Calendar
2024-07-30
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
22.13
USD
Average target price
26.59
USD
Spread / Average Target
+20.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.75% | 6.45B | |
| +18.77% | 125B | |
| +14.05% | 108B | |
| -7.16% | 23.64B | |
| +2.07% | 22.39B | |
| -10.79% | 17.78B | |
| -41.74% | 16.43B | |
| -13.47% | 16.34B | |
| +2.23% | 13.56B | |
| +27.13% | 11.59B |
- Stock Market
- Equities
- EXEL Stock
- News Exelixis, Inc.
- Transcript : Exelixis, Inc. Presents at Deutsche Bank 42nd Annual Health Care Conference, May-03-2017 11
